This study aimed to test the hypothesis that baseline levels of urinary MCP-1 and EGF or their ratio would predict rapid decline of estimated GFR in a cohort of T2DM patients with CKD independent of conventional clinical risk factors. This evidence concerns the gene CCL2 and type 2 diabetes mellitus.